Growth Factor Serums Promise Acne Repair. The Research Barely Covers Acne.

Epidermal growth factor has spent the last few years migrating from wound-care clinics into serums marketed for breakouts, wrinkles, and "skin renewal" alike. A new review in the Journal of Cosmetic Dermatology tries to pin down what that ingredient can actually document for acne, and the gap between the mechanism and the marketing turns out to be wide.

The authors, led by Nasim Gholizadeh, searched PubMed from its inception through June 30, 2026, for anything connecting epidermal growth factor and its receptor, EGFR, to acne, scarring, keratinocyte behavior, sebocytes, or wound repair. The resulting picture starts at the cellular level: EGF signaling can push keratinocytes to proliferate, migrate, and modulate inflammatory activity, processes plausibly relevant to a follicle trying to heal. The review is explicit about the catch, though: "most of this evidence derives from non-acne cellular or wound-healing models," not from acne lesions themselves.

When the authors narrowed their search to active acne vulgaris, the clinical record shrank to two small, short-term split-face trials, the design where one side of a patient's face receives treatment and the other serves as its own control. Those studies reported preliminary within-study improvement in lesion-related outcomes, a real signal but far short of the standardized, comparator-controlled evidence needed to call EGF a treatment for breakouts.

A separate, somewhat larger body of research addresses a different problem: scars that have already formed. Some of that work applies topical EGF serum alone to atrophic acne scarring, and the review rates that evidence weak. A broader set of studies tests recombinant human EGF as an adjunct to fractional laser resurfacing, where the laser performs the resurfacing and the growth factor is layered on to see whether it changes the healing outcome.

The review draws a hard line between these two literatures: neither the scar studies nor the laser-adjunct studies say anything about preventing scars from forming in the first place, and none of it can be extrapolated back to treating active acne. Even within the laser-adjunct setting, the authors found protocols too heterogeneous and evidence too limited to support a routine recommendation.

Their conclusion is a holding pattern rather than a verdict: topical EGF should remain investigational until larger randomized trials use standardized formulations, active comparators, indication-specific outcomes, and longer safety follow-up. For a category of serums that already lines drugstore shelves promising to calm breakouts and fade their aftermath, the review's real contribution is narrower and more useful than a yes-or-no answer, it is a map of exactly which claims have two small trials behind them and which have none at all.